{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:12:30Z","timestamp":1784931150098,"version":"3.55.0"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antipsychotics are recommended after first\u2010episode psychosis. Knowledge on the current use patterns in real\u2010world settings is thus important to inform clinical practice. We aimed to describe antipsychotic initiation during 1\u2009year after first\u2010episode psychosis and its associated factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Population\u2010based cohort study using linked nationwide health and population registers from Norway. The study population comprised 8052 persons aged 16\u201345\u2009years with first\u2010episode psychosis diagnosed in secondary care (ICD\u201010 F20, F22\u2013F29) in the period 2011\u20132019. Initiation of antipsychotic use was defined as being dispensed antipsychotics (ATC N05A, excl. lithium) at least once from \u221290 to +365\u2009days from secondary care diagnosis of first\u2010episode psychosis. Antipsychotic polypharmacy during follow\u2010up was defined as having at least 90\u2009days with overlapping drug use periods modeled using the Prescriptions to Drug Use Periods method. Adjusted risk ratios (aRRs) with 95% confidence intervals (CIs) for the association between socioeconomic and clinical factors and initiation of antipsychotic use were calculated using modified Poisson regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 4413 persons (54.8%) initiated antipsychotic use after first\u2010episode psychosis with proportions ranging from 45.5% in 2012 to 62.1% in 2019. Oral formulations of olanzapine (34.9%), quetiapine (21.2%), and aripiprazole (11.6%) were most common at initiation, whereas long\u2010acting injectables (LAIs) and clozapine were rarely used. Among the initiators, 13.8% started a polypharmacy period lasting more than 90\u2009days. Factors associated with antipsychotic initiation were lower age (aRR 1.14, 95% CI 1.08\u20131.21; 26\u201335\u2009years vs. 36\u201345\u2009years), higher education (1.11, 1.05\u20131.18), being employed (1.04, 1.00\u20131.09), being hospitalized (1.13, 1.09\u20131.18), being diagnosed late in the study period (1.16, 1.11\u20131.22; 2017\u20132019 vs. 2011\u20132013), or with previously diagnosed bipolar disorder, depression, or anxiety disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The antipsychotic use pattern is largely within the current clinical guideline. Primary non\u2010compliance and disease severity may explain the socioeconomic and clinical differences related to initiation of antipsychotic use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/acps.13776","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T02:20:32Z","timestamp":1732933232000},"page":"537-547","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Initiation of Antipsychotics During the First Year After First\u2010Episode Psychosis: A Population\u2010Based Study"],"prefix":"10.1111","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5337-8619","authenticated-orcid":false,"given":"I.","family":"Odsbu","sequence":"first","affiliation":[{"name":"Department of Chronic Diseases The Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2417-4059","authenticated-orcid":false,"given":"A.","family":"Hamina","sequence":"additional","affiliation":[{"name":"Niuvanniemi Hospital  Kuopio Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Hjellvik","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases The Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Handal","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases The Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Haram","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine University of Oslo  Oslo Norway"},{"name":"Division of Mental Health and Addiction Oslo University Hospital  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tesli","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Suicide The Norwegian Institute of Public Health  Oslo Norway"},{"name":"Department of Psychiatry \u00d8stfold Hospital  Gr\u00e5lum Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tanskanen","sequence":"additional","affiliation":[{"name":"Niuvanniemi Hospital  Kuopio Finland"},{"name":"Department of Clinical Neuroscience, Division of Insurance Medicine Karolinska Institutet  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Taipale","sequence":"additional","affiliation":[{"name":"Niuvanniemi Hospital  Kuopio Finland"},{"name":"Department of Clinical Neuroscience, Division of Insurance Medicine Karolinska Institutet  Stockholm Sweden"},{"name":"School of Pharmacy University of Eastern Finland  Kuopio Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.7.1091"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.1.19"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2024.02.018"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.10.027"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbac041"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.113.127753"},{"key":"e_1_2_10_9_1","unstructured":"The Norwegian Directorate of Health \u201cNasjonal faglig retningslinje for utredning behandling og oppf\u00f8lging av personer med psykoselidelser\u201d[in Norwegian] (2013) https:\/\/www.helsedirektoratet.no\/retningslinjer\/psykoselidelser\/Utredning %20behandling%20og%20oppf%C3%B8lging%20av%20personer%20med%20psykoselidelser%20%E2%80%93%20Nasjonal%20faglig%20retningslinje%20(fullversjon).pdf\/_\/attachment\/inline\/a2c5a070\u201019d8\u201047df\u2010b86c\u20109e9e6002c514:5981d8d6a0c9f6086a20bc426eb552f12a2d81dd\/Utredning %20behandling%20og%20oppf%C3%B8lging%20av%20personer%20med%20psykoselidelser%20%E2%80%93%20Nasjonal%20faglig%20retningslinje%20(fullversjon).pdf."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013881"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-126"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-9-24"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/08039480600583662"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-024-05513-9"},{"key":"e_1_2_10_15_1","unstructured":"The Norwegian Government \u201cMedication\u2010Free Treatment Alternative for Patients in Psychiatric Care\u201d[in Norwegian] accessed Feb 16 2024 https:\/\/www.regjeringen.no\/no\/dokumentarkiv\/regjeringen\u2010solberg\/aktuelt\u2010regjeringen\u2010solberg\/hod\/nyheter\/2015\/medikamentfri\u2010behandling\u2010for\u2010psykisk\u2010syke\u2010i\u2010alle\u2010helseregioner\/id2464240\/."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-015-0140-z"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh090"},{"key":"e_1_2_10_18_1","unstructured":"L. C.Berentzen \u201cShared Experiences From Clinical Practice: Medical Report From Early Psychosis Treatment Oslo University Hospital\u201d[in Norwegian] (2022) https:\/\/www.oslo\u2010universitetssykehus.no\/avdelinger\/klinikk\u2010psykisk\u2010helse\u2010og\u2010avhengighet\/forsknings\u2010og\u2010innovasjonsavdelingen\u2010i\u2010pha\/regionalt\u2010kompetansesenter\u2010for\u2010tidlig\u2010intervensjon\u2010ved\u2010psykoser\/medisinrapport\u2010fra\u2010tidlig\u2010psykosebehandling."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182a1cd2e"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10081224"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14010006"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S117321"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/08039488.2020.1854853"},{"key":"e_1_2_10_24_1","unstructured":"Danish Medicines Council \u201cAntipsychotics for Treatment of Psychosis in Adults\u201d[in Danish] accessed June 27 2024 https:\/\/medicinraadet.dk\/anbefalinger\u2010og\u2010vejledninger\/behandlingsvejledninger\u2010og\u2010laegemiddelrekommandationer\/antipsykotika\u2010til\u2010voksne."},{"key":"e_1_2_10_25_1","unstructured":"R.Stockholm' \u201cKloka Listan. Swedish Recommendations for Treatment of Psychosis\u201d[in Swedish] accessed June 26 2024 https:\/\/klokalistan.se\/terapiomrade\/psykiatri\/psykos.html."},{"key":"e_1_2_10_26_1","unstructured":"The Swedish National Board of Health and Welfare \u201cNational Guidelines for Treatment of Schizophrenia and Schizophrenia\u2010Like Conditions\u201d[in Swedish] accessed June 26 2024 https:\/\/www.socialstyrelsen.se\/kunskapsstod\u2010och\u2010regler\/regler\u2010och\u2010riktlinjer\/nationella\u2010riktlinjer\/riktlinjer\u2010och\u2010utvarderingar\/schizofreni\/."},{"issue":"3","key":"e_1_2_10_27_1","article-title":"Olanzapine Versus Other Atypical Antipsychotics for Schizophrenia","author":"Komossa K.","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbac014"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v65n0211"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213\u2010006\u20100413\u20104"},{"key":"e_1_2_10_31_1","unstructured":"The Norwegian Ministry of Health and Care Services \u201cBetter Decisions Better Treatments\u201d[in Norwegian] accessed Nov 6 2024 https:\/\/www.regjeringen.no\/no\/dokumenter\/bedre\u2010beslutninger\u2010bedre\u2010behandling\/id2985104\/."},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7893.2009.00148.x"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1176\/ps.49.2.196"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v63n1007"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.7090su1cj"},{"key":"e_1_2_10_36_1","unstructured":"The Norwegian Institute of Public Health \u201cWholesaler\u2010Based Drug Statistics in Norway\u201daccessed March 4 2024 https:\/\/www.fhi.no\/en\/he\/drug\/om\u2010den\u2010grossistbaserte\u2010legemiddelforbruksstatistikken\/."}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acps.13776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T23:17:26Z","timestamp":1741735046000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acps.13776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/acps.13776"],"URL":"https:\/\/doi.org\/10.1111\/acps.13776","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/ACPS.13776\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.13776\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.13776\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.13776\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.13776\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.13776\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.13776\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/ACPS.13776\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"2024-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}